Recently, CanSinoBIO initiated a Phase Ⅲ clinical trial of its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) Menhycia®, successfully enrolling its first participant in Indonesia. This trial aims to expand the applicable population, and evaluate the safety and immunogenicity of the vaccine in adults aged 18 to 55 years. As early as June 2022, Menhycia®, developed by CanSinoBIO, has been officially approved for market launch in China, targeting infants and young children under the [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Permalink

Disclaimer

Cansino Biologics Inc. published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 03:02:02 UTC.